Zhongsheng Peng

Meizhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.

Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.

Journal: Technology in cancer research & treatment
Published: May 27, 2026

A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer.

A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer.

Journal: Frontiers in oncology
Published: March 13, 2026

Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window.

Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window.

Journal: Cancer biology & medicine
Published: February 10, 2025

Long-term survival case of SCLC transformation after Osimertinib resistance in EGFR-mutant NSCLC: Benefits from chemo-immunotherapy combined with anti-angiogenic therapy followed by Osimertinib rechallenge.

Long-term survival case of SCLC transformation after Osimertinib resistance in EGFR-mutant NSCLC: Benefits from chemo-immunotherapy combined with anti-angiogenic therapy followed by Osimertinib rechallenge.

Journal: Cancer letters
Published: October 08, 2024

A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC.

A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC.

Journal: Scientific reports
Published: June 21, 2024

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.

Journal: Journal of translational medicine
Published: May 31, 2024

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation.

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation.

Journal: Genes & diseases
Published: February 22, 2024

Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis.

Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis.

Journal: Heliyon
Published: January 16, 2024

Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.

Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.

Journal: Molecular cancer therapeutics
Published: July 16, 2023

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers.

Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers.

Journal: Therapeutic advances in medical oncology
Published: July 13, 2023

Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12.

Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12.

Journal: Frontiers in immunology
Published: March 26, 2023
Showing 1-11 of 11

Last Updated: 09/26/2026